Denali Therapeutics Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price
Denali Therapeutics Inc. (DNLI) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price of $21.15 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2026-03-31 was $21.30, a 19.26% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2025-03-31 was $26.38, a 7.44% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2024-03-31 was $28.50, a 28.23% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for the quarter ending 2023-03-31 was $39.71, a 9.83% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2025 was $25.16, a 20.15% decline from fiscal 2024.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2024 was $31.51, a 20.51% decline from fiscal 2023.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2023 was $39.64, a 5.21% decline from fiscal 2022.
- Denali Therapeutics Inc. share-based compensation arrangements by share-based payment award, options, forfeitures in period, weighted average exercise price for fiscal 2022 was $41.82, a 18.30% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $21.15 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | $21.30 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $25.16 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $26.27 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | $27.48 10-Q · filed 2025-08-11 | |||
| 2025-03-31 | $26.38 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $31.51 10-K · filed 2025-02-27 | |||
| 2024-09-30 | $31.29 10-Q · filed 2024-11-06 | |||
| 2024-06-30 | $30.95 10-Q · filed 2024-08-01 | |||
| 2024-03-31 | $28.50 10-Q · filed 2024-05-07 | |||
| 2023-12-31 | $39.64 10-K · filed 2024-02-28 | |||
| 2023-09-30 | $40.37 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $41.33 10-Q · filed 2023-08-08 | |||
| 2023-03-31 | $39.71 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $41.82 10-K · filed 2023-02-27 | |||
| 2022-09-30 | $40.64 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $37.46 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $44.04 10-Q · filed 2022-05-05 | |||
| 2021-12-31 | $35.35 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $34.89 10-Q · filed 2021-11-04 | |||
| 2021-06-30 | $32.76 10-Q · filed 2021-08-04 | |||
| 2021-03-31 | $26.77 10-Q · filed 2021-05-05 | |||
| 2020-12-31 | $20.57 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $20.60 10-Q · filed 2020-11-05 | |||
| 2020-06-30 | $19.08 10-Q · filed 2020-08-07 | |||
| 2020-03-31 | $18.02 10-Q · filed 2020-05-07 | |||
| 2019-12-31 | $16.72 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $16.65 10-Q · filed 2019-11-06 | |||
| 2019-06-30 | $16.30 10-Q · filed 2019-08-06 | |||
| 2019-03-31 | $16.11 10-Q · filed 2019-05-08 | |||
| 2018-12-31 | $12.48 10-K · filed 2019-03-12 | |||
| 2018-09-30 | $10.36 10-Q · filed 2018-11-08 | |||
| 2018-06-30 | $9.56 10-Q · filed 2018-08-09 | |||
| 2018-03-31 | $3.48 10-Q · filed 2018-05-11 | |||
| 2017-12-31 | $2.21 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |